As the number of people living with HIV worldwide continues to grow, HIV-related illness remains a leading cause of death. It is likely to continue to be a significant cause of premature mortality in the coming decades. Antiretroviral therapy (ART) enables people to regain control over their lives, dignity, productivity and employment and contributes to reducing further transmission of HIV and tuberculosis (TB). People living with HIV have a basic human right to equitable access to quality, efficient and sustainable interventions for HIV prevention and treatment.

Dans sa Lettre aux partenaires 2011, le Directeur exécutif de l’ONUSIDA, Michel Sidibé, appelle à une restructuration de la riposte au sida. Il met en évidence une série de six nouveaux repères pour guider la riposte mondiale au sida dans son avancée.

Le présent document examine comment les pays peuvent tirer parti des flexibilités de l’Accord sur les droits de propriété intellectuelle qui touchent au commerce (ADPIC) de l’Organisation mondiale du commerce (OMC) pour améliorer l’accès aux traitements du VIH.

(UNAIDS/UNDPKO, May 2011)

Many countries with a high burden of HIV infection also face burgeoning epidemics of noncommunicable diseases. Similar to HIV, noncommunicable diseases are most frequent in low- and middle-income countries, and the age-adjusted death rates from noncommunicable diseases are nearly twice as high in low- and middle-income countries as in high-income countries. People living with HIV often also have high rates of noncommunicable diseases. With HIV programmes rapidly expanding, people with HIV are living longer and ageing, and are developing non-HIV-related chronic conditions similar to the rest of the population.

This report provides evidence of how much we have achieved and weighs that against our vision for the future: zero new HIV infections, zero discrimination and zero AIDS‑related deaths. In these pages you will find scientific analysis, personal insights and the results of extensive national and regional consultations at the front lines of the AIDS response. While perspectives differ, one simple truth emerges: we cannot break the arc of this epidemic – where five people were newly infected for every three starting treatment in 2010 – if we adopt a 'business as usual' approach.

We live in a time of unprecedented hope for the 33.3 million people living with HIV worldwide. Antiretroviral therapy (ART) offers the promise of a full and fulfilling life. Now people living with HIV can raise their families, work and pursue their dreams. But a thief is in our midst—one that is routinely robbing people, and the countries they live in, of their futures. Every minute, three people living with HIV have their lives snatched away by tuberculosis (TB). Africa, hit hard by HIV, is also hit hard by TB. TB is the main cause of death in people living with HIV.

Le Guide des bonnes pratiques de participation offrent aux bailleurs de fonds, aux promoteurs et aux responsables de la mise en oeuvre des essais, des directives systématiques visant à faire participer efficacement les parties prenantes à la conception et à la conduite des essais de méthodes biomédicales de prévention du VIH.

Les objectifs premiers de la Santé positive, Dignité et Prévention consistent à améliorer la dignité, la qualité et la durée de vie des personnes vivant avec le VIH ; ces objectifs, une fois atteints, auront un impact bénéfique sur leurs partenaires, leurs familles et leurs communautés, notamment avec la réduction de la probabilité de nouvelles infections.

This publication describes how the Joint United Nations Programme on HIV/AIDS (UNAIDS) partners with country partners and the Global Fund to Fight AIDS, Tuberculosis and Malaria (Global Fund) to strengthen the global response to AIDS and to accelerate progress towards universal access to HIV prevention, treatment, care and support, and the achievement of the Millennium Development Goals (MDGs).